Who Paid My Doc
Edwin Lafontaine
Dentist, General Practice Ceiba, PR Doctor of Dentistry
NPI 1629185822 CMS profile 551682
557B Calle Julian Rivera, Ceiba, PR 00735
General payments
$1,758
Research payments
$0
Ownership & investment interest
$0
Through program year 2024, Edwin Lafontaine of Ceiba, PR is reported in the CMS Open Payments database as having received $1,758 across 11 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 89th percentile of Dentist, General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
2 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2024 | General | $183 | 2 | |
| 2022 | General | $1,575 | 9 |
Beside peers
- Edwin Lafontaine
- Dentist, General Practice median
- Middle half of Dentist, General Practice
- National median
In program year 2025, general payments to Edwin Lafontaine were reported at $0. Among 41,122 Dentist, General Practice profiles paid that year, the median was $75 and the middle half received between $27 and $200.
Show as a table
| Year | Edwin Lafontaine | Dentist, General Practice median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $61 | $23–$158 | $163 |
| 2020 | $0 | $73 | $24–$142 | $114 |
| 2021 | $0 | $75 | $25–$184 | $132 |
| 2022 | $1,575 | $75 | $27–$198 | $149 |
| 2023 | $0 | $77 | $28–$200 | $160 |
| 2024 | $183 | $74 | $27–$187 | $164 |
| 2025 | $0 | $75 | $27–$200 | $169 |
Breakdown
Prescribing to Medicare patients
Part D · data year 2024 · 2 drugsPart D claims
86
Drug cost
$931
Branded share of claims
0%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Clindamycin Hcl | Generic | 74 | $850 | |
| Amoxicillin | Generic | 12 | $81 |
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 110,731 Part D prescribers listed as Dentist; they describe a distribution and say nothing about conduct.
Records
11 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Dentist, General Practice in Puerto Rico
Luis Camacho
Dentist, General Practice · Mayaguez, PR
Carlos Abreu Girald
Dentist, General Practice · Aguadilla, PR
Sigrid Mojica-Preciado
Dentist, General Practice · Bayamon, PR
Angel Hernandez
Dentist, General Practice · Vega Baja, PR
Gladys Maldonado
Dentist, General Practice · Bayamon, PR
Ivan Sandoval
Dentist, General Practice · Bayamon, PR
Related records
Dentist, General Practice in Puerto Rico
Practitioners in the same specialty and state, ranked by reported value.
All Dentist, General Practice
Everyone recorded under this specialty, nationwide.
Doctors in Puerto Rico
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.